
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3411750</article-id><article-id pub-id-type="pmid">22879966</article-id><article-id pub-id-type="publisher-id">PONE-D-12-08074</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0042401</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Genetics</subject><subj-group><subject>Human Genetics</subject><subj-group><subject>Genetic Association Studies</subject><subject>Genome-Wide Association Studies</subject></subj-group></subj-group><subj-group><subject>Population Genetics</subject><subj-group><subject>Genetic Polymorphism</subject></subj-group></subj-group><subj-group><subject>Genetics of Disease</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Cardiovascular</subject><subj-group><subject>Coronary Artery Disease</subject><subject>Interventional Cardiology</subject><subject>Vascular Biology</subject></subj-group></subj-group><subj-group><subject>Epidemiology</subject><subj-group><subject>Cardiovascular Disease Epidemiology</subject><subject>Genetic Epidemiology</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Systematic Testing of Literature Reported Genetic Variation Associated with Coronary Restenosis: Results of the GENDER Study </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running-head">Gene-Set Analysis of Coronary Restenosis</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Verschuren</surname><given-names>Jeffrey J. W.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Trompet</surname><given-names>Stella</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Postmus</surname><given-names>Iris</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sampietro</surname><given-names>M. Lourdes</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Heijmans</surname><given-names>Bastiaan T.</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Houwing-Duistermaat</surname><given-names>Jeanine J.</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Slagboom</surname><given-names>P. Eline</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jukema</surname><given-names>J. Wouter</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref><xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref><xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Department Human Genetics, Leiden University Medical Center, Leiden, The Netherlands</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Molecular Epidemiology, Leiden University Medical Center, Leiden, The Netherlands</addr-line>
</aff><aff id="aff5">
<label>5</label>
<addr-line>Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, The Netherlands</addr-line>
</aff><aff id="aff6">
<label>6</label>
<addr-line>Netherlands Consortium for Healthy Ageing, Leiden, The Netherlands</addr-line>
</aff><aff id="aff7">
<label>7</label>
<addr-line>Interuniversity Cardiology Institute of the Netherlands (ICIN), Utrecht, The Netherlands</addr-line>
</aff><aff id="aff8">
<label>8</label>
<addr-line>Durrer Center for Cardiogenetic Research, Amsterdam, The Netherlands</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Gong</surname><given-names>Yan</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>College of Pharmacy, University of Florida, United States of America</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>j.w.jukema@lumc.nl</email></corresp><fn fn-type="COI-statement"><p><text><SENT sid="1" pm="."><plain>Competing Interests: The authors have declared that no competing interests exist. </plain></SENT>
</text></p></fn><fn fn-type="con"><p><text><SENT sid="2" pm="."><plain>Conceived and designed the experiments: JJWV ST IP MLS BTH JJH-D EPS JWJ. </plain></SENT>
<SENT sid="3" pm="."><plain>Performed the experiments: JJWV ST MLS. </plain></SENT>
<SENT sid="4" pm="."><plain>Analyzed the data: JJWV ST. </plain></SENT>
<SENT sid="5" pm="."><plain>Contributed reagents/materials/analysis tools: ST IP MLS BTH JWJ. </plain></SENT>
<SENT sid="6" pm="."><plain>Wrote the paper: JJWV ST IP BTH JWJ. </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>3</day><month>8</month><year>2012</year></pub-date><volume>7</volume><issue>8</issue><elocation-id>e42401</elocation-id><history><date date-type="received"><day>19</day><month>3</month><year>2012</year></date><date date-type="accepted"><day>5</day><month>7</month><year>2012</year></date></history><permissions><copyright-statement>© 2012 Verschuren et al</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Verschuren et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title><text><SENT sid="7" pm="."><plain>Background </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="8" pm="."><plain>Coronary restenosis after percutaneous coronary intervention still remains a significant problem, despite all medical advances. </plain></SENT>
<SENT sid="9" pm="."><plain>Unraveling the mechanisms leading to restenosis development remains challenging. </plain></SENT>
<SENT sid="10" pm="."><plain>Many studies have identified genetic markers associated with restenosis, but consistent replication of the reported markers is scarce. </plain></SENT>
<SENT sid="11" pm="."><plain>The aim of the current study was to analyze the joined effect of previously in literature reported candidate genes for restenosis in the GENetic DEterminants of Restenosis (GENDER) databank. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="12" pm="."><plain>Methodology/Principal Findings </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="13" pm="."><plain>Candidate genes were selected using a MEDLINE search including the terms ‘genetic polymorphism’ and ‘coronary restenosis’. </plain></SENT>
<SENT sid="14" pm="."><plain>The final set included 36 genes. </plain></SENT>
<SENT sid="15" pm="."><plain>Subsequently, all single nucleotide polymorphisms (SNPs) in the genomic region of these genes were analyzed in GENDER using set-based analysis in PLINK. </plain></SENT>
<SENT sid="16" pm="."><plain>The GENDER databank contains genotypic data of 2,571,586 SNPs of 295 cases with restenosis and 571 matched controls. </plain></SENT>
<SENT sid="17" pm="."><plain>The set, including all 36 literature reported genes, was, indeed, significantly associated with restenosis, p = 0.024 in the GENDER study. </plain></SENT>
<SENT sid="18" pm="."><plain>Subsequent analyses of the individual genes demonstrated that the observed association of the complete set was determined by 6 of the 36 genes. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="19" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="20" pm="."><plain>Despite overt inconsistencies in literature, with regard to individual candidate gene studies, this is the first study demonstrating that the joint effect of all these genes together, indeed, is associated with restenosis. </plain></SENT>
</text></SecTag></p></sec></abstract><funding-group><funding-statement>This work was funded by grants from the Interuniversity Cardiology Institute of the Netherlands (ICIN) <ext-link ext-link-type="uri" xlink:href="http://www.icin.nl/">http://www.icin.nl/</ext-link>, the European Community Framework FP7 Programme under grant agreement [n° HEALTH-F2-2009-223004; <ext-link ext-link-type="uri" xlink:href="http://cordis.europa.eu/projects/90569_en.html">http://cordis.europa.eu/projects/90569_en.html</ext-link>], the Center for Medical Systems Biology (CMSB) [<ext-link ext-link-type="uri" xlink:href="http://www.cmsb.nl">http://www.cmsb.nl</ext-link>], a center of excellence approved by the Netherlands Genomics Initiative/Netherlands Organisation for Scientific Research (NWO), and the Netherlands Consortium for Healthy Ageing (NCHA) [<ext-link ext-link-type="uri" xlink:href="http://www.healthy-ageing.nl">http://www.healthy-ageing.nl</ext-link>]. JWJ is an established clinical investigator of the Netherlands Heart Foundation (2001D032) [<ext-link ext-link-type="uri" xlink:href="http://www.hartstichting.nl/">http://www.hartstichting.nl/</ext-link>]. The funders had no role in study design, data collection and analysis, decision to publish or the preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="8"/></counts></article-meta></front><body><SecTag type="INTRO"><sec id="s1"><title><text><SENT sid="21" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="22" pm="."><plain>Restenosis is a complex disease for which the causative mechanisms have not yet been fully identified. </plain></SENT>
<SENT sid="23" pm="."><plain>Despite medical advances, restenosis still remains a significant complication after percutaneous coronary intervention (PCI).[1] Identification of risk factors and underlying mechanisms could not only be useful in risk stratification of patients, they also contribute to our understanding of this condition. </plain></SENT>
<SENT sid="24" pm="."><plain>In addition, these factors could provide evidence on which to base individually tailored treatment and aid in the development of novel therapeutic modalities.[2] Unraveling the mechanisms leading to restenosis development remains challenging. </plain></SENT>
<SENT sid="25" pm="."><plain>Genetic susceptibility is known to play a role in the individuals risk of developing this complication.[1] Many studies have focused on identification of genetic markers associated with restenosis. </plain></SENT>
<SENT sid="26" pm="."><plain>Over the last decades genetic research has developed from candidate gene approaches [3]–[5] to multiplex arrays [6] and finally to genome wide association studies (GWAS).[7] Genetic variation in large array of plausible candidate genes have been associated with restenosis, however, consistent replication of the reported markers is scarce.[1] Possible explanations for this lack of consistency are the small sample size of many (especially relative more dated) studies, phenotype heterogeneity and lack of proper replication cohorts. </plain></SENT>
</text></p><p><text><SENT sid="27" pm="."><plain>Currently more and more GWAS are being performed, investigating many diseases, including cardiovascular diseases.[8], [9] An advantage of GWAS is the hypothesis-free approach of this method, enabling identification of new genetic loci associated with the disease of interest. </plain></SENT>
<SENT sid="28" pm="."><plain>With respect to restenosis, a disadvantage of the GWAS approach is that due to the complexity of the disease the effect size of individual genetic markers is likely to be small and therefore hard to detect. </plain></SENT>
<SENT sid="29" pm="."><plain>Moreover, the availability of (large) replication cohorts is very limited. </plain></SENT>
<SENT sid="30" pm="."><plain>In 2011, the first GWAS on restenosis in the GENetic DEterminants of Restenosis (GENDER) study identified a new susceptibility locus on chromosome 12.[7] The fact that this GWAS only identified this previously unknown locus does not mean that genetic variation in the previously proposed candidate genes does not affect restenosis development. </plain></SENT>
<SENT sid="31" pm="."><plain>It merely indicates that the influence of other individual markers is probably too small to detect in the GWAS setting. </plain></SENT>
<SENT sid="32" pm="."><plain>Especially for the complex traits, a more appropriate approach to interpret GWAS data is to analyze the combined effect of a single nucleotide polymorphism (SNP) set, grouped per pathway or gene region.[10] To date, investigation into a possible joined effect of multiple genetic markers for restenosis has not been performed. </plain></SENT>
</text></p><p><text><SENT sid="33" pm="."><plain>The goal of the current study is to investigate whether the last decade of research on genetics of restenosis has led to a set of genes that is associated with restenosis in a set-based analysis using the available genotypic data of the GENDER databank. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="methods" id="s2"><title><text><SENT sid="34" pm="."><plain>Methods </plain></SENT>
</text></title><sec id="s2a"><title><text><SENT sid="35" pm="."><plain>Gene Selection </plain></SENT>
</text></title><p><text><SENT sid="36" pm="."><plain>Candidate genes previously associated with restenosis were selected after a search of literature of papers published up to November 2011. </plain></SENT>
<SENT sid="37" pm="."><plain>Genes were identified searching MEDLINE using keywords as ‘genetic polymorphism’, ‘candidate gene’, ‘restenosis’ and ‘percutaneous coronary intervention’. </plain></SENT>
<SENT sid="38" pm="."><plain>Selection criteria included a sample size of &gt;250 patients and the observation of a significant association of a SNP with restenosis. </plain></SENT>
<SENT sid="39" pm="."><plain>The final set included 36 genes. </plain></SENT>
<SENT sid="40" pm="."><plain>All available SNPs from the GENDER GWAS databank within a 10-Kb window around these genes were analyzed. </plain></SENT>
</text></p></sec><sec id="s2b"><title><text><SENT sid="41" pm="."><plain>Study Population </plain></SENT>
</text></title><p><text><SENT sid="42" pm="."><plain>The design of GENDER and the genome-wide association study (GWAS), which has been performed in a subset of this study population, have both been described previously.[7], [11] In brief, GENDER included 3,104 consecutive unrelated symptomatic patients treated successfully by PCI for angina. </plain></SENT>
<SENT sid="43" pm="."><plain>The study protocol conforms to the Declaration of Helsinki and was approved by the ethics committees of each participating institution. </plain></SENT>
<SENT sid="44" pm="."><plain>Written informed consent was obtained from each participant before the PCI procedure. </plain></SENT>
<SENT sid="45" pm="."><plain>During a follow-up period of 9 months, the endpoint clinical restenosis, defined as renewed symptoms requiring target vessel revascularization (TVR) either by repeated PCI or CABG, by death from cardiac causes or myocardial infarction not attributable to another coronary event than the target vessel, was recorded. </plain></SENT>
<SENT sid="46" pm="."><plain>During follow-up, 346 patients developed clinical restenosis. </plain></SENT>
<SENT sid="47" pm="."><plain>Blood samples were collected at the index procedure for DNA isolation. </plain></SENT>
<SENT sid="48" pm="."><plain>The GWAS was performed in 325 cases of restenosis and 630 controls matched by gender, age, and some possible confounding clinical variables for restenosis in the GENDER study such as total occlusion, diabetes, current smoking and residual stenosis. </plain></SENT>
<SENT sid="49" pm="."><plain>Genotyping was performed using the Illumina Human 610-Quad Beadchips following the manufacturer’s instructions. </plain></SENT>
<SENT sid="50" pm="."><plain>After genotyping, samples and genetic markers were subjected to a stringent quality control protocol. </plain></SENT>
<SENT sid="51" pm="."><plain>The final dataset consisted of 866 individuals (295 cases, 571 controls) and 556,099 SNPs that passed all quality control criteria, together covering 89% of the common genetic variation in the European population.[7], [12] Imputation was performed with MACH software based on the HapMap II release 22 CEU build 36 using the default settings.[13] This program infers missing genotypes based on the known genotypic data of the samples together with haplotypes from a reference population provided by HapMap taken into account the degree of linkage disequilibrium (LD). </plain></SENT>
<SENT sid="52" pm="."><plain>After subsequent quality control, we excluded SNPs for further analyses with a call rate lower than 95% (n = 3335) or with a significant deviation from Hardy–Weinberg equilibrium (HWE) in controls (P&lt;0.00001) (n = 79). </plain></SENT>
<SENT sid="53" pm="."><plain>The final GENDER Biobank dataset consisted of 866 (295 cases, 571 controls) individuals and 2,571,586 SNPs. </plain></SENT>
</text></p></sec><sec id="s2c"><title><text><SENT sid="54" pm="."><plain>Statistical Analysis </plain></SENT>
</text></title><p><text><SENT sid="55" pm="."><plain>The statistical analyses were performed using the set-based test of PLINK v1.07.[14] During this test, first a single SNP analysis of all SNPs within the set is performed. </plain></SENT>
<SENT sid="56" pm="."><plain>Subsequently a mean SNP statistic is calculated from the single SNP statistics of a maximum amount of independent SNPs below a certain p-value threshold. </plain></SENT>
<SENT sid="57" pm="."><plain>If SNPs are not independent and the LD (expressed in R2) is above a certain threshold, the SNP with the lowest p-value in the single SNP analysis is selected. </plain></SENT>
<SENT sid="58" pm="."><plain>This analysis is repeated in a certain amount of permutations of the phenotype. </plain></SENT>
<SENT sid="59" pm="."><plain>An empirical p-value for the SNP set is computed by calculating the number of times the test statistic of the simulated SNP sets exceeds that of the original SNP set. </plain></SENT>
<SENT sid="60" pm="."><plain>For the analysis of this study, the parameters were set to p-value threshold &lt;0.05, R2 threshold &lt;0.1, maximum number of SNPs  = 5 and 10,000 permutations. </plain></SENT>
</text></p><p><text><SENT sid="61" pm="."><plain>Initially, the set including all 36 genes is tested as a whole for the association with restenosis. </plain></SENT>
<SENT sid="62" pm="."><plain>Subsequent analysis of the individual genes will be justified only when the complete set is significantly associated with the endpoint. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec id="s3"><title><text><SENT sid="63" pm="."><plain>Results </plain></SENT>
</text></title><p><text><SENT sid="64" pm="."><plain>Patient characteristics are presented in Table 1. </plain></SENT>
<SENT sid="65" pm="."><plain>No significant differences were found between cases and controls regarding the known risk factors for restenosis (age, diabetes, smoking, stenting and previous restenosis). </plain></SENT>
<SENT sid="66" pm="."><plain>Hypertension and multivessel disease were more common in the cases compared to the controls. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone-0042401-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0042401.t001</object-id><label>Table 1</label><caption><title><text><SENT sid="67" pm="."><plain>Demographic, clinical and lesion characteristics of the study population. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0042401-t001-1" xlink:href="pone.0042401.t001"/></alternatives><table-wrap-foot><fn id="nt101"><label/><p><text><SENT sid="68" pm="."><plain>Values were given as n (%) or mean ± SD. </plain></SENT>
<SENT sid="69" pm="."><plain>Patients using anti-diabetic medication or insulin at study entry were considered to be diabetics. </plain></SENT>
<SENT sid="70" pm="."><plain>Hypertension was defined as a blood pressure of either above 160 mmHg systolic or 90 mmHg diastolic. </plain></SENT>
<SENT sid="71" pm="."><plain>Hypercholesterolaemia was defined as total cholesterol concentrations of above 5 mmol/L. </plain></SENT>
<SENT sid="72" pm="."><plain>BMI: body mass index, MI: myocardial infarction. </plain></SENT>
<SENT sid="73" pm="."><plain>P-values are determined by Pearsons Chi-Square (discrete variables) or unpaired 2-sided t-test (continuous variables). </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="74" pm="."><plain>In Figure 1 the QQ-plot of the GENDER GWAS after imputation is shown, demonstrating that no genomic inflation has occurred in this analysis (lambda  = 1.027). </plain></SENT>
<SENT sid="75" pm="."><plain>The complete set of 36 genes, previously associated with restenosis in literature, contained 2,581 SNPs. </plain></SENT>
<SENT sid="76" pm="."><plain>A detailed description of the individual studies and candidate genes can be found in Table 2. </plain></SENT>
<SENT sid="77" pm="."><plain>The largest gene was chemokine (C-X3-C motif) receptor 1 (CX3CR1) of 316.54 kb, contributing 384 SNPs (14.8%), and glutathione peroxidase 1 (GPX1) was with 1.18 kb the smallest gene, only contributing 8 SNPs (0.3%). </plain></SENT>
<SENT sid="78" pm="."><plain>Analysis of the complete set using the set-based test demonstrated a significant association with clinical restenosis, with an empirical p-value of 0.024. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone-0042401-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0042401.g001</object-id><label>Figure 1</label><caption><title><text><SENT sid="79" pm="."><plain>Q-Q plot for the GWAS after imputation on clinical restenosis in the GENDER study population. </plain></SENT>
<SENT sid="80" pm="."><plain>Lambda  = 1.027. </plain></SENT>
</text></title></caption><graphic xlink:href="pone.0042401.g001"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="pone-0042401-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0042401.t002</object-id><label>Table 2</label><caption><title><text><SENT sid="81" pm="."><plain>Candidate genes and the studies that reported their association with restenosis. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0042401-t002-2" xlink:href="pone.0042401.t002"/></alternatives><table-wrap-foot><fn id="nt102"><label>a</label><p><text><SENT sid="82" pm="."><plain>The direction of the association between genetic variation and the risk of restenosis, when effect size is not available;↓ protective effect, ↑ deleterious effect. </plain></SENT>
<SENT sid="83" pm="."><plain>Entrez nr; unique gene ID number used in NCBI database. </plain></SENT>
<SENT sid="84" pm="."><plain>Abbreviations: UK, unknown; NS, not significant; OR, odds ratio; HR, hazard ratio; RR, relative risk; Ref, reference. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="85" pm="."><plain>To determine which genes are mainly responsible for this association we subsequently investigated the association of the individual gene based sets. </plain></SENT>
<SENT sid="86" pm="."><plain>Six of the 36 genes were demonstrated to have an empirical p-value below 0.05 (Table 3). </plain></SENT>
<SENT sid="87" pm="."><plain>In order of descending p-values the associated genes are; angiotensin II receptor type 1 (AGTR, p = 0.028), glutathione peroxidase 1 (GPX1, p = 0.025), K(lysine) acetyltransferase 2B (KAT2B, also known as PCAF, p = 0.023), matrix metallopeptidase 12 (MMP12, p = 0.019), fibrinogen beta chain (FGB, p = 0.013) and vitamin D receptor (VDR, p = 0.012). </plain></SENT>
<SENT sid="88" pm="."><plain>Detailed information on the individual SNPs in these genes is depicted in Table 4. </plain></SENT>
<SENT sid="89" pm="."><plain>The SNP with the lowest individual p-value was rs11574027 in the VDR gene, p = 1.4E-04. </plain></SENT>
<SENT sid="90" pm="."><plain>In the complete GWAS analysis, which has been published in 2011 [7], this SNP ranked 116th. </plain></SENT>
<SENT sid="91" pm="."><plain>The strongest association in that analysis was found with a SNP in an intergenic region on chromosome 12, p = 1.0E-06. </plain></SENT>
</text></p><p><text><SENT sid="92" pm="."><plain>Logistic regression models with and without the 11 SNPs described in Table 4 demonstrated that together these SNPs explained 9.0% (R Square improved from 0.008 to 0.098) of the occurrence of clinical restenosis in this cohort. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone-0042401-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0042401.t003</object-id><label>Table 3</label><caption><title><text><SENT sid="93" pm="."><plain>Results of individual gene set-based analysis of genes previously associated with restenosis. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0042401-t003-3" xlink:href="pone.0042401.t003"/></alternatives><table-wrap-foot><fn id="nt103"><label/><p><text><SENT sid="94" pm="."><plain>Chromosome and genomic region based on HapMap Rel 28 Phase II+III. </plain></SENT>
<SENT sid="95" pm="."><plain>P-value based on permutation (10,000). </plain></SENT>
<SENT sid="96" pm="."><plain>Abbreviations: SNPs, number of SNPs in genomic region including 10 kb window; Sign.SNPs, number of SNPs with p&lt;0.05; Indep.SNPs, number of significant and independent SNPs, considering threshold of R2&lt;0.1. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="pone-0042401-t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0042401.t004</object-id><label>Table 4</label><caption><title><text><SENT sid="97" pm="."><plain>Significantly associated SNPs of the 6 top genes. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0042401-t004-4" xlink:href="pone.0042401.t004"/></alternatives><table-wrap-foot><fn id="nt104"><label/><p><text><SENT sid="98" pm="."><plain>SNP, single nucleotide polymorphism; Chr, chromosome; bp, base pair; MAF, minor allele frequency in control group; OR, odds ratio. </plain></SENT>
<SENT sid="99" pm="."><plain>The imputation quality indicates the average posterior probability for the most likely genotype generated by MACH, ranging from 0–1. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="100" pm="."><plain>As a final analysis we removed the 6 significantly associated genes from the complete set. </plain></SENT>
<SENT sid="101" pm="."><plain>Subsequent analysis of the subset of the other 30 genes did not demonstrate a remaining joined effect, p = 0.65 after 10,000 permutations. </plain></SENT>
</text></p></sec></SecTag><SecTag type="DISCUSS"><sec id="s4"><title><text><SENT sid="102" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="103" pm="."><plain>With this study we aimed at clarifying the ambiguities regarding genetic predisposition for developing restenosis after PCI. </plain></SENT>
<SENT sid="104" pm="."><plain>We show that the joined effect of the complete spectrum of candidate genes, so far proposed to be involved in the restenotic process, results in a significant association with restenosis. </plain></SENT>
<SENT sid="105" pm="."><plain>This association is determined by six individual genes. </plain></SENT>
<SENT sid="106" pm="."><plain>Analyzing a subset containing the 30 genes not associated with the endpoint on an individual basis, did not show a remaining joined effect, making the involvement of genetic variation in these genes on restenosis development more unlikely. </plain></SENT>
</text></p><p><text><SENT sid="107" pm="."><plain>The six associated genes span a wide range of different functions underlining the complexity of the disease. </plain></SENT>
<SENT sid="108" pm="."><plain>When examining the biological pathways with involvement of these genes, only the VDR and KAT2B genes share a common pathway. </plain></SENT>
<SENT sid="109" pm="."><plain>The genes are both involved in the Vitamin D receptor pathway described by BioCarta.[15] This pathway mainly involves the transcriptional regulating capacities of this receptor and is involved in controlling cellular growth, differentiation and apoptosis. </plain></SENT>
<SENT sid="110" pm="."><plain>Since these processes are all thought to be important contributors to the restenotic process, this indeed is a plausible pathway to be involved in restenosis development.[1]. </plain></SENT>
</text></p><p><text><SENT sid="111" pm="."><plain>The rationale of set-based analysis is to overcome the marginally weak effect of single SNPs by analyzing a set of SNPs, since these SNPs could jointly have strong genetic effects. </plain></SENT>
<SENT sid="112" pm="."><plain>Most studies utilizing the candidate gene approach analyzed only one or at most a few SNPs within the gene of interest. </plain></SENT>
<SENT sid="113" pm="."><plain>The likelihood that exactly those SNPs are the causal or associated SNPs is of course small. </plain></SENT>
<SENT sid="114" pm="."><plain>A broader approach, like this set-based analysis, is therefore more likely to detect an associated gene by combining multiple SNPs with a possible marginal individual effect.[16], [17] For the current study we used the PLINK software [14], although multiple statistical programs are available for this type of analysis. </plain></SENT>
<SENT sid="115" pm="."><plain>Gui et al. compared 7 tests analyzing the WTCCC Crohn’s Disease dataset.[18] One of their overall conclusions was that the set-based test in PLINK was the most powerful algorithm. </plain></SENT>
<SENT sid="116" pm="."><plain>Another study, applying PLINK set-based test, Global test, GRASS and SNP ratio test, for the analysis of three pathways regarding human longevity observed similar results with the different tests.[19]. </plain></SENT>
</text></p><p><text><SENT sid="117" pm="."><plain>For the current study we analyzed the data using a threshold of linkage disequilibrium defined by R2≥0.1. </plain></SENT>
<SENT sid="118" pm="."><plain>The standard setting in PLINK is a R2 of 0.5. </plain></SENT>
<SENT sid="119" pm="."><plain>In our opinion this threshold is too high for the intended analysis for this study. </plain></SENT>
<SENT sid="120" pm="."><plain>A higher threshold will include more SNPs in higher LD, which would be unfavorable, since we were interested in independent loci contributing to the risk of restenosis. </plain></SENT>
<SENT sid="121" pm="."><plain>By decreasing this threshold, only SNPs were selected that had a R2 below 0.1, and thus independent of each other. </plain></SENT>
</text></p><p><text><SENT sid="122" pm="."><plain>Although hypertension and multivessel disease were more frequent in cases compared to controls we decided not to correct for these variables. </plain></SENT>
<SENT sid="123" pm="."><plain>In the complete GENDER population these variables were not independent predictors for restenosis development [11], so the differences in the current subpopulation likely resulted by chance during the selection process. </plain></SENT>
<SENT sid="124" pm="."><plain>Also, other studies provide no convincing data that hypertension is related to restenosis [1]. </plain></SENT>
<SENT sid="125" pm="."><plain>It is therefore unlikely that previous associations of some of the current candidates genes (VDR, FGB, AGTR1 and GPX1) with hypertension[20]–[23], have influenced our results, although this cannot be completely excluded. </plain></SENT>
</text></p><p><text><SENT sid="126" pm="."><plain>A limitation of the current study could be that we analyzed imputed genotypic data, which introduces some amount of uncertainty. </plain></SENT>
<SENT sid="127" pm="."><plain>However, since we were interested in the combined effect of SNPs, an extensive genomic coverage was paramount for this analysis. </plain></SENT>
<SENT sid="128" pm="."><plain>Only analyzing the genotyped GWAS data would have resulted in the coverage of some of the smaller genes by only 1 or 2 SNPs. </plain></SENT>
<SENT sid="129" pm="."><plain>Therefore we decided that the more extensive genomic coverage of the imputed dataset outweighed the small introduction of possible error. </plain></SENT>
<SENT sid="130" pm="."><plain>A second limitation is that the analyses were only performed in the GENDER population. </plain></SENT>
<SENT sid="131" pm="."><plain>Availability of other populations with thorough genetic data on restenosis is however very limited. </plain></SENT>
<SENT sid="132" pm="."><plain>To our knowledge, the GWAS on restenosis in the GENDER population is the first, and only, examining this endpoint on a genome wide scale. </plain></SENT>
<SENT sid="133" pm="."><plain>Finally, the conclusions of this study are only based on genetic analyses. </plain></SENT>
<SENT sid="134" pm="."><plain>Functional studies should be performed to elucidate the biological consequences of these findings. </plain></SENT>
</text></p><p><text><SENT sid="135" pm="."><plain>In conclusion, with these results we demonstrate that the efforts in unraveling the genetic factors influencing the risk of restenosis of the last years has resulted in a set of genes that joint together is indeed likely to be associated with restenosis, despite the overt inconsistencies of the individual studies. </plain></SENT>
<SENT sid="136" pm="."><plain>Confirmation of the association of these genes with the occurrence of restenosis after PCI helps our understanding of the genetic etiology of the disease. </plain></SENT>
<SENT sid="137" pm="."><plain>Future additional research strategies, like biological pathway analysis of GWAS data or even (exome) sequencing, might help us find the missing heritability of restenosis after PCI and increase our knowledge of the biological mechanistic background of restenosis development. </plain></SENT>
<SENT sid="138" pm="."><plain>This knowledge could subsequently result in identification of new treatment targets or development of novel preventive measure or risk stratification models. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="REF"><ref-list><title>References</title><ref id="pone.0042401-Jukema1"><text><SENT sid="139" pm="."><plain>1 JukemaJW, VerschurenJJ, AhmedTA, QuaxPH (2012) Restenosis after PCI. </plain></SENT>
<SENT sid="140" pm="."><plain>Part 1: pathophysiology and risk factors. Nat Rev Cardiol 9: 53–62. </plain></SENT>
</text></ref><ref id="pone.0042401-Jukema2"><text><SENT sid="141" pm="."><plain>2 JukemaJW, AhmedTA, VerschurenJJ, QuaxPH (2012) Restenosis after PCI. </plain></SENT>
<SENT sid="142" pm="."><plain>Part 2: prevention and therapy. Nat Rev Cardiol 9: 79–90. </plain></SENT>
</text></ref><ref id="pone.0042401-Kastrati1"><text><SENT sid="143" pm="."><plain>3 KastratiA, KochW, BergerPB, MehilliJ, StephensonK, et al (2000) Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. J Am Coll Cardiol 36: 2168–2173.11127457 </plain></SENT>
</text></ref><ref id="pone.0042401-Koch1"><text><SENT sid="144" pm="."><plain>4 KochW, BottigerC, MehilliJ, vonBN, NeumannFJ, et al (2001) Association of a CD18 gene polymorphism with a reduced risk of restenosis after coronary stenting. Am J Cardiol 88: 1120–1124.11703955 </plain></SENT>
</text></ref><ref id="pone.0042401-Monraats1"><text><SENT sid="145" pm="."><plain>5 MonraatsPS, PiresNM, SchepersA, AgemaWR, BoestenLS, et al (2005) Tumor necrosis factor-alpha plays an important role in restenosis development. FASEB J 19: 1998–2004.16319143 </plain></SENT>
</text></ref><ref id="pone.0042401-Monraats2"><text><SENT sid="146" pm="."><plain>6 MonraatsPS, PiresNM, AgemaWR, ZwindermanAH, SchepersA, et al (2005) Genetic inflammatory factors predict restenosis after percutaneous coronary interventions. Circulation 112: 2417–2425.16230497 </plain></SENT>
</text></ref><ref id="pone.0042401-Sampietro1"><text><SENT sid="147" pm="."><plain>7 SampietroML, TrompetS, VerschurenJJ, TalensRP, DeelenJ, et al (2011) A genome-wide association study identifies a region at chromosome 12 as a potential susceptibility locus for restenosis after percutaneous coronary intervention. Hum Mol Genet 20: 4748–4757.21878436 </plain></SENT>
</text></ref><ref id="pone.0042401-ODonnell1"><text><SENT sid="148" pm="."><plain>8 O’DonnellCJ, NabelEG (2011) Genomics of cardiovascular disease. N Engl J Med 365: 2098–2109.22129254 </plain></SENT>
</text></ref><ref id="pone.0042401-Keating1"><text><SENT sid="149" pm="."><plain>9 KeatingBJ, TischfieldS, MurraySS, BhangaleT, PriceTS, et al (2008) Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS One 3: e3583.18974833 </plain></SENT>
</text></ref><ref id="pone.0042401-Ma1"><text><SENT sid="150" pm="."><plain>10 MaL, HanS, YangJ, DaY (2010) Multi-locus test conditional on confirmed effects leads to increased power in genome-wide association studies. PLoS One 5: e15006.21103364 </plain></SENT>
</text></ref><ref id="pone.0042401-Agema1"><text><SENT sid="151" pm="."><plain>11 AgemaWR, MonraatsPS, ZwindermanAH, de WinterRJ, TioRA, et al (2004) Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre-drug-eluting stent era. Eur Heart J 25: 1163–1170.15231375 </plain></SENT>
</text></ref><ref id="pone.0042401-Sampietro2"><text><SENT sid="152" pm="."><plain>12 SampietroML, PonsD, de KnijffP, SlagboomPE, ZwindermanA, et al (2009) A genome wide association analysis in the GENDER study. Neth Heart J 17: 262–264.19789690 </plain></SENT>
</text></ref><ref id="pone.0042401-Li1"><text><SENT sid="153" pm="."><plain>13 LiY, WillerCJ, DingJ, ScheetP, AbecasisGR (2010) MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 34: 816–834.21058334 </plain></SENT>
</text></ref><ref id="pone.0042401-Purcell1"><text><SENT sid="154" pm="."><plain>14 PurcellS, NealeB, Todd-BrownK, ThomasL, FerreiraMA, et al (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559–575.17701901 </plain></SENT>
</text></ref><ref id="pone.0042401-Biocarta1"><text><SENT sid="155" pm="."><plain>15Biocarta website. </plain></SENT>
<SENT sid="156" pm="."><plain>Biocarta pathway. </plain></SENT>
<SENT sid="157" pm="."><plain>Available: http://www.biocarta.com/pathfiles/h_vdrpathway.asp. </plain></SENT>
<SENT sid="158" pm="."><plain>Accessed 2012 Mar 1.. </plain></SENT>
</text></ref><ref id="pone.0042401-Fridley1"><text><SENT sid="159" pm="."><plain>16 FridleyBL, BiernackaJM (2011) Gene set analysis of SNP data: benefits, challenges, and future directions. Eur J Hum Genet 19: 837–843.21487444 </plain></SENT>
</text></ref><ref id="pone.0042401-Torkamani1"><text><SENT sid="160" pm="."><plain>17 TorkamaniA, TopolEJ, SchorkNJ (2008) Pathway analysis of seven common diseases assessed by genome-wide association. Genomics 92: 265–272.18722519 </plain></SENT>
</text></ref><ref id="pone.0042401-Gui1"><text><SENT sid="161" pm="."><plain>18 GuiH, LiM, ShamPC, ChernySS (2011) Comparisons of seven algorithms for pathway analysis using the WTCCC Crohn’s Disease dataset. BMC Res Notes 4: 386.21981765 </plain></SENT>
</text></ref><ref id="pone.0042401-Deelen1"><text><SENT sid="162" pm="."><plain>19 DeelenJ, UhHW, MonajemiR, vanHD, ThijssenPE, et al (2011) Gene set analysis of GWAS data for human longevity highlights the relevance of the insulin/IGF-1 signaling and telomere maintenance pathways. </plain></SENT>
<SENT sid="163" pm="."><plain>Age (Dordr ) In press. 10.1007/s11357–011–9340–3 [doi]. </plain></SENT>
</text></ref><ref id="pone.0042401-Swapna1"><text><SENT sid="164" pm="."><plain>20 SwapnaN, VamsiUM, UshaG, PadmaT (2011) Risk conferred by FokI polymorphism of vitamin D receptor (VDR) gene for essential hypertension. Indian J Hum Genet 17: 201–206.22345993 </plain></SENT>
</text></ref><ref id="pone.0042401-Kolz1"><text><SENT sid="165" pm="."><plain>21 KolzM, BaumertJ, GohlkeH, GrallertH, DoringA, et al (2009) Association study between variants in the fibrinogen gene cluster, fibrinogen levels and hypertension: results from the MONICA/KORA study. Thromb Haemost 101: 317–324.19190816 </plain></SENT>
</text></ref><ref id="pone.0042401-Niu1"><text><SENT sid="166" pm="."><plain>22 NiuW, QiY (2010) Association of the angiotensin II type I receptor gene +1166 A&gt;C polymorphism with hypertension risk: evidence from a meta-analysis of 16474 subjects. Hypertens Res 33: 1137–1143.20703234 </plain></SENT>
</text></ref><ref id="pone.0042401-Mansego1"><text><SENT sid="167" pm="."><plain>23 MansegoML, SolarGM, AlonsoMP, MartinezF, SaezGT, et al (2011) Polymorphisms of antioxidant enzymes, blood pressure and risk of hypertension. J Hypertens 29: 492–500.21178785 </plain></SENT>
</text></ref><ref id="pone.0042401-Falcone1"><text><SENT sid="168" pm="."><plain>24 FalconeC, EmanueleE, BuzziMP, BalleriniL, RepettoA, et al (2007) The-374T/A variant of the rage gene promoter is associated with clinical restenosis after coronary stent placement. Int J Immunopathol Pharmacol 20: 771–777.18179750 </plain></SENT>
</text></ref><ref id="pone.0042401-Shim1"><text><SENT sid="169" pm="."><plain>25 ShimCY, ParkS, YoonSJ, ParkHY, KimHT, et al (2007) Association of RAGE gene polymorphisms with in-stent restenosis in non-diabetic Korean population. Cardiology 107: 261–268.16954682 </plain></SENT>
</text></ref><ref id="pone.0042401-Gross1"><text><SENT sid="170" pm="."><plain>26 GrossCM, PerrotA, GeierC, PoschMG, HassfeldS, et al (2007) Recurrent in-stent restenosis is not associated with the angiotensin-converting enzyme D/I, angiotensinogen Thr174Met and Met235Thr, and the angiotensin-II receptor 1 A1166C polymorphism. J Invasive Cardiol 19: 261–264.17541127 </plain></SENT>
</text></ref><ref id="pone.0042401-Wijpkema1"><text><SENT sid="171" pm="."><plain>27 WijpkemaJS, van HaelstPL, MonraatsPS, BruinenbergM, ZwindermanAH, et al (2006) Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1. Pharmacogenet Genomics 16: 331–337.16609364 </plain></SENT>
</text></ref><ref id="pone.0042401-Oguri1"><text><SENT sid="172" pm="."><plain>28 OguriM, KatoK, HibinoT, YokoiK, SegawaT, et al (2007) Genetic risk for restenosis after coronary stenting. Atherosclerosis 194: e172–e178.17275003 </plain></SENT>
</text></ref><ref id="pone.0042401-Shimada1"><text><SENT sid="173" pm="."><plain>29 ShimadaK, MiyauchiK, MokunoH, WatanabeY, IwamaY, et al (2004) Promoter polymorphism in the CD14 gene and concentration of soluble CD14 in patients with in-stent restenosis after elective coronary stenting. Int J Cardiol 94: 87–92.14996480 </plain></SENT>
</text></ref><ref id="pone.0042401-Tiroch1"><text><SENT sid="174" pm="."><plain>30 TirochK, KochW, MehilliJ, BottigerC, SchomigA, et al (2009) P27 and P53 gene polymorphisms and restenosis following coronary implantation of drug-eluting stents. Cardiology 112: 263–269.18758183 </plain></SENT>
</text></ref><ref id="pone.0042401-vanTiel1"><text><SENT sid="175" pm="."><plain>31 van TielCM, BontaPI, RittersmaSZ, BeijkMA, BradleyEJ, et al (2009) p27kip1-838C&gt;A single nucleotide polymorphism is associated with restenosis risk after coronary stenting and modulates p27kip1 promoter activity. Circulation 120: 669–676.19667240 </plain></SENT>
</text></ref><ref id="pone.0042401-Oguri2"><text><SENT sid="176" pm="."><plain>32 OguriM, KatoK, HibinoT, YokoiK, SegawaT, et al (2007) Identification of a polymorphism of UCP3 associated with recurrent in-stent restenosis of coronary arteries. Int J Mol Med 20: 533–538.17786284 </plain></SENT>
</text></ref><ref id="pone.0042401-Niessner1"><text><SENT sid="177" pm="."><plain>33 NiessnerA, MarculescuR, KvakanH, HaschemiA, EndlerG, et al (2005) Fractalkine receptor polymorphisms V2491 and T280M as genetic risk factors for restenosis. Thromb Haemost 94: 1251–1256.16411402 </plain></SENT>
</text></ref><ref id="pone.0042401-Horibe1"><text><SENT sid="178" pm="."><plain>34 HoribeH, YamadaY, IchiharaS, WataraiM, YanaseM, et al (2004) Genetic risk for restenosis after coronary balloon angioplasty. Atherosclerosis 174: 181–187.15135268 </plain></SENT>
</text></ref><ref id="pone.0042401-Tiroch2"><text><SENT sid="179" pm="."><plain>35 TirochKA, SibbingD, KochW, Roosen-RungeT, MehilliJ, et al (2010) Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J 160: 506–512.20826260 </plain></SENT>
</text></ref><ref id="pone.0042401-Monraats3"><text><SENT sid="180" pm="."><plain>36 MonraatsPS, RanaJS, ZwindermanAH, de MaatMP, KasteleinJP, et al (2005) -455G/A polymorphism and preprocedural plasma levels of fibrinogen show no association with the risk of clinical restenosis in patients with coronary stent placement. Thromb Haemost 93: 564–569.15735811 </plain></SENT>
</text></ref><ref id="pone.0042401-Pons1"><text><SENT sid="181" pm="."><plain>37 PonsD, MonraatsPS, de MaatMP, PiresNM, QuaxPH, et al (2007) The influence of established genetic variation in the haemostatic system on clinical restenosis after percutaneous coronary interventions. Thromb Haemost 98: 1323–1328.18064331 </plain></SENT>
</text></ref><ref id="pone.0042401-MartinezRios1"><text><SENT sid="182" pm="."><plain>38 Martinez-RiosMA, Pena-DuqueMA, FragosoJM, Delgadillo-RodriguezH, Rodriguez-PerezJM, et al (2009) Tumor necrosis factor alpha and interleukin 10 promoter polymorphisms in Mexican patients with restenosis after coronary stenting. Biochem Genet 47: 707–716.19585232 </plain></SENT>
</text></ref><ref id="pone.0042401-Koch2"><text><SENT sid="183" pm="."><plain>39 KochW, TirochK, vonBN, SchomigA, KastratiA (2003) Tumor necrosis factor-alpha, lymphotoxin-alpha, and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting. Cytokine 24: 161–171.14572794 </plain></SENT>
</text></ref><ref id="pone.0042401-Monraats4"><text><SENT sid="184" pm="."><plain>40 MonraatsPS, KurreemanFA, PonsD, SewgobindVD, de VriesFR, et al (2007) Interleukin 10: a new risk marker for the development of restenosis after percutaneous coronary intervention. Genes Immun 8: 44–50.17122782 </plain></SENT>
</text></ref><ref id="pone.0042401-Marculescu1"><text><SENT sid="185" pm="."><plain>41 MarculescuR, MlekuschW, ExnerM, SabetiS, MichorS, et al (2003) Interleukin-1 cluster combined genotype and restenosis after balloon angioplasty. Thromb Haemost 90: 491–500.12958619 </plain></SENT>
</text></ref><ref id="pone.0042401-Zee1"><text><SENT sid="186" pm="."><plain>42 ZeeRY, Fernandez-OrtizA, MacayaC, PintorE, Fernandez-CruzA, et al (2003) IL-1 cluster genes and occurrence of post-percutaneous transluminal coronary angioplasty restenosis: a prospective, angiography-based evaluation. Atherosclerosis 171: 259–264.14644395 </plain></SENT>
</text></ref><ref id="pone.0042401-Monraats5"><text><SENT sid="187" pm="."><plain>43 MonraatsPS, RanaJS, NiermanMC, PiresNM, ZwindermanAH, et al (2005) Lipoprotein lipase gene polymorphisms and the risk of target vessel revascularization after percutaneous coronary intervention. J Am Coll Cardiol 46: 1093–1100.16168296 </plain></SENT>
</text></ref><ref id="pone.0042401-Chung1"><text><SENT sid="188" pm="."><plain>44 ChungSL, ChiouKR, CharngMJ (2006) 677TT polymorphism of methylenetetrahydrofolate reductase in combination with low serum vitamin B12 is associated with coronary in-stent restenosis. Catheter Cardiovasc Interv 67: 349–355.16489563 </plain></SENT>
</text></ref><ref id="pone.0042401-Koch3"><text><SENT sid="189" pm="."><plain>45 KochW, NdrepepaG, MehilliJ, BraunS, BurghartzM, et al (2003) Homocysteine status and polymorphisms of methylenetetrahydrofolate reductase are not associated with restenosis after stenting in coronary arteries. Arterioscler Thromb Vasc Biol 23: 2229–2234.14604831 </plain></SENT>
</text></ref><ref id="pone.0042401-Gomma1"><text><SENT sid="190" pm="."><plain>46 GommaAH, ElrayessMA, KnightCJ, HaweE, FoxKM, et al (2002) The endothelial nitric oxide synthase (Glu298Asp and-786T&gt;C) gene polymorphisms are associated with coronary in-stent restenosis. Eur Heart J 23: 1955–1962.12473258 </plain></SENT>
</text></ref><ref id="pone.0042401-Pons2"><text><SENT sid="191" pm="."><plain>47 PonsD, MonraatsPS, ZwindermanAH, de MaatMP, DoevendansPA, et al (2009) Metabolic background determines the importance of NOS3 polymorphisms in restenosis after percutaneous coronary intervention: A study in patients with and without the metabolic syndrome. Dis Markers 26: 75–83.19407362 </plain></SENT>
</text></ref><ref id="pone.0042401-Gorchakova1"><text><SENT sid="192" pm="."><plain>48 GorchakovaO, KochW, vonBN, MehilliJ, SchomigA, et al (2003) Association of a genetic variant of endothelial nitric oxide synthase with the 1 year clinical outcome after coronary stent placement. Eur Heart J 24: 820–827.12727149 </plain></SENT>
</text></ref><ref id="pone.0042401-Rudez1"><text><SENT sid="193" pm="."><plain>49 RudezG, PonsD, LeebeekF, MonraatsP, SchrevelM, et al (2008) Platelet receptor P2RY12 haplotypes predict restenosis after percutaneous coronary interventions. Hum Mutat 29: 375–380.18175333 </plain></SENT>
</text></ref><ref id="pone.0042401-Bottiger1"><text><SENT sid="194" pm="."><plain>50 BottigerC, KochW, LahnC, MehilliJ, vonBN, et al (2003) 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting. Am Heart J 146: 855–861.14597935 </plain></SENT>
</text></ref><ref id="pone.0042401-Pons3"><text><SENT sid="195" pm="."><plain>51 PonsD, TrompetS, de CraenAJ, ThijssenPE, QuaxPH, et al (2011) Genetic variation in PCAF, a key mediator in epigenetics, is associated with reduced vascular morbidity and mortality: evidence for a new concept from three independent prospective studies. Heart 97: 143–150.21062767 </plain></SENT>
</text></ref><ref id="pone.0042401-Neugebauer1"><text><SENT sid="196" pm="."><plain>52 NeugebauerP, Goldbergova-PavkovaM, KalaP, BocekO, JerabekP, et al (2009) Nuclear receptors gene polymorphisms and risk of restenosis and clinical events following coronary stenting. Vnitr Lek 55: 1135–1140.20070029 </plain></SENT>
</text></ref><ref id="pone.0042401-Koch4"><text><SENT sid="197" pm="."><plain>53 KochW, JungV, vonBN, SchomigA, KastratiA (2004) Peroxisome proliferator-activated receptor gamma gene polymorphisms and restenosis in diabetic patients after stenting in coronary arteries. Diabetologia 47: 1126–1127.15156314 </plain></SENT>
</text></ref><ref id="pone.0042401-Rittersma1"><text><SENT sid="198" pm="."><plain>54 RittersmaSZ, BoekholdtSM, KochKT, GeuzebroekR, BaxM, et al (2004) Thrombospondin gene polymorphisms and the risk of angiographic coronary in-stent restenosis. Am J Med 116: 499–500.15047045 </plain></SENT>
</text></ref><ref id="pone.0042401-Kojima1"><text><SENT sid="199" pm="."><plain>55 KojimaS, IwaiN, TagoN, OnoK, OhmiK, et al (2004) p53Arg72Pro polymorphism of tumour suppressor protein is associated with luminal narrowing after coronary stent placement. Heart 90: 1069–1070.15310710 </plain></SENT>
</text></ref><ref id="pone.0042401-Zee2"><text><SENT sid="200" pm="."><plain>56 ZeeRY, CookNR, KimCA, Fernandez-CruzA, LindpaintnerK (2004) TP53 haplotype-based analysis and incidence of post-angioplasty restenosis. Hum Genet 114: 386–390.14740296 </plain></SENT>
</text></ref><ref id="pone.0042401-Monraats6"><text><SENT sid="201" pm="."><plain>57 MonraatsPS, FangY, PonsD, PiresNM, PolsHA, et al (2010) Vitamin D receptor: a new risk marker for clinical restenosis after percutaneous coronary intervention. Expert Opin Ther Targets 14: 243–251.20095921 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
